Evaluation status available after sign-in
About the journal
Blood Immunology & Cellular Therapy is an open-access journal published by Elsevier in United States, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,000 USD. Declared review time at DOAJ: 12 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 3050-5976
- Country
- United States
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,000 USD
- Articles in DOAJ
- 46
- Declared review time
- 12 weeks
- Declared peer-review model
- other
Index listings
- DOAJ · 2026-03-09
- Indexing
- DOAJ
- APC
- 3,000 USD
- Declared review time (DOAJ)
- 12 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
46
Most recent article
last month
Average review time (journal-declared via DOAJ)
12weeks
Works in OpenAlex
69
Last recorded publication year
2026
Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
4
i10-index
0
From OpenAlex open data (CC0).
Editorial & policy10
- Added to DOAJ
- 2026-03-09
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 81%
- ORCID iDs in current deposits
- 91%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 9919050937306676
Classification4
Subjects (DOAJ)
Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. AllergyMedicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs
LCC codes
RC581-607RC633-647.5
Subject areas
- CAR-T cell therapy research
- CAR-T cell therapy research
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Show all subjects (75)
- T-cell and B-cell Immunology
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Cancer Immunotherapy and Biomarkers
- Cutaneous lymphoproliferative disorders research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Monoclonal and Polyclonal Antibodies Research
- Immunodeficiency and Autoimmune Disorders
- Biomedical Ethics and Regulation
- Virus-based gene therapy research
- Protein Degradation and Inhibitors
- Biomedical Ethics and Regulation
- Transplantation: Methods and Outcomes
- Immune Cell Function and Interaction
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Neutropenia and Cancer Infections
- Protein Degradation and Inhibitors
- CRISPR and Genetic Engineering
- Protein Degradation and Inhibitors
- CRISPR and Genetic Engineering
- Renal Transplantation Outcomes and Treatments
- Neutropenia and Cancer Infections
- Cytomegalovirus and herpesvirus research
- Neutropenia and Cancer Infections
- Hemophilia Treatment and Research
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- CRISPR and Genetic Engineering
- Viral-associated cancers and disorders
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Hemophilia Treatment and Research
- Mesenchymal stem cell research
- Health Systems, Economic Evaluations, Quality of Life
- EEG and Brain-Computer Interfaces
- Mesenchymal stem cell research
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Biomedical Ethics and Regulation
- Acute Myeloid Leukemia Research
- Autoimmune Neurological Disorders and Treatments
- HER2/EGFR in Cancer Research
- Renal Transplantation Outcomes and Treatments
- Platelet Disorders and Treatments
- Platelet Disorders and Treatments
- Renal Transplantation Outcomes and Treatments
- Acute Myeloid Leukemia Research
- HER2/EGFR in Cancer Research
Keywords (DOAJ)
- hematology
- cellular therapy
- gene therapy
- non-cellular immunotherapy
- regulatory issues
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ